Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report issued on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and issued a $5.00 price objective on shares of Minerva Neurosciences in a research report on Wednesday.

Minerva Neurosciences Trading Up 1.0 %

Shares of NASDAQ NERV opened at $2.34 on Friday. Minerva Neurosciences has a 1-year low of $2.26 and a 1-year high of $13.49. The company has a 50-day moving average of $2.62 and a two-hundred day moving average of $2.79. The company has a market cap of $16.38 million, a PE ratio of -5.33 and a beta of 0.18.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.